GeneriCo is led by a team of executives who have developed numerous specialty generic products. GeneriCo's expedited success is the result of its unique collaboration model that allows for formulation expertise, risk-sharing partnerships and speed to market. GeneriCo has validated its speed to market initiative via the success of its first 4 development candidates which will be submitted in the next 8 months to the US FDA for approval.